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Tightening Tight Junctions with Compression Therapy
To the Editor:
The control of vascular permeability is dependent on the
opening and closure or the dissociation and formation of interen-
dothelial cell junctions (Tsukita et al, 1999). Previous investi-
gations revealed that paracellular permeability across endothelial
cell layers is determined by tight junctions (TJs) that seal the
intercellular space (Tsukita et al, 2001). There is accumulating
evidence that occludin (OCLN) and notably claudins (CLDNs)
constitute the backbone of tight-junction strands. They belong
to a family of transmembrane proteins which are proteins with
cytoplasmic amino and carboxyl termini and two extracellular
domains.
Chronic venous insu⁄ciency is associated with perimalleolar
edema of the lower extremity. It is well known that the presence
of intradermal edema may predispose to the development of
severe stages of chronic venous insu⁄ciency such as leg ulceration
(Herouy et al, 1998;Valencia et al, 2001). Elevated hydrostatic pres-
sure had been thought to be the underlying mechanism of ele-
vated leakage of £uid from insu⁄cient vessels. However, there
had been no analysis until now as to how tight junction mole-
cules could be involved in the formation of edema in patients
with chronic venous insu⁄ciency. The treatment of chronic
venous insu⁄ciency requires improved venous £uid return from
the leg and the prevention of perivascular £uid accumulation
(Pierson et al, 1983; Fletcher et al, 1997). Medical elastic compres-
sion stockings are therefore a cornerstone of treatment in these
patients since they prevent stasis and support the resorption of
perivascular £uid. In the following study we were prompted to
question whether ¢rst tight junctions play a role and second
compression therapy has an e¡ect on the expression pattern
of tight junction molecules in patients with chronic venous
insu⁄ciency.
A combined clinical and experimental study was conducted in
patients su¡ering from edema (n¼ 8; mean age 62,8 SD79,1),
venous leg ulcers (n¼ 8; mean age 66,3 SD711,4) and sex-matched
healthy controls (n¼ 8; mean age 64,3 SD710,7) after informed
written consent and approval from the health authority. Patients
with edema and with venous leg ulcers have been characterized
according to the international clinical CEAP-classi¢cation of
chronic venous insu⁄ciency (CVI). The diagnosis was con¢rmed
clinically by duplex scanning, Doppler sonography and by
photoplethysmography. Patients with edema and venous leg
ulcers were treated with graded elastic compression stockings
(Bauerfeind Phlebologie GmbH & Co.KG, Zeulenroda, Ger-
many) during a period of four weeks. Biopsy specimens were
taken 1 cm proximal to the medial malleolus in healthy indivi-
duals and in patients before and four weeks after compression
therapy. The mRNA and protein expression of speci¢c tight
junction molecules OCLN, CLDN-1, CLDN-3 and CLDN-5
from tissue specimens were analyzed by semiquantitative reverse
transcription followed by polymerase chain reaction (RT-PCR)
and Western blot. Designed primers for detecting the mRNA
Expression with RT-PCR were as follows: OCLN [Sense 50 -
TCTGCAACGTTGTCAGAAGG-03, Antisense 50 -ACTCAGTC
CTTTAGCACAACAGC-03 (bp 204)], CLDN-1 [Sense 50 -TCA
GCA CTG CCC TGC CCC AGT-03, Antisense 50 -TGG TGT
TGG GTA AGA GGT TGT-03 (bp 506)], CLDN-3 [Sense 50 -
AAG GCC AAG ATC ACC ATC GTG-03, Antisense 50 -AGA
CGTAGT CCT TGC GGT CGT-03 (bp 304)], CLDN-5 [Sense
5-0ATG TCG TGC GTG GTG CAG AG-03, Antisense 50 -GGT
GCA GAC CCA GGC GCC GCA-03 (bp 413)] and GAPDH
[Sense 50 -CCACCCATGGCAAATTCCATGGCA-30, Antisense
50 -TCT AGACGGCAGGTCAGGTCCACC-30 (598 bp)]. In
order to assure linear cDNA ampli¢cation in our experiments,
di¡erent amplifying cycles (22^36) were checked. Linear ampli-
¢cation was obtained between 22 and 32 cycles. Equal protein
loading was con¢rmed by GAPDH immunoreactivity, quanti¢-
cation by densitometric scanning was normalized to GAPDH.
Antibodies against OCLN (mono-Ab. OC-3F10) against
CLDN-1 (polyAb. JAY.8), CLDN-3 (polyAb. Z23.JM), CLDN-5
(Ab. Z43.JK) for immunohistochemistry and Westernblot were
purchased from Zymed Laboratories (San Francisco, CA, USA).
The intensity of bands and blots was quanti¢ed measuring the
optical density (OD) with an OneDscan computer software
package.
Quanti¢cation performed determing the expression for tight
junction molecules displayed diminished expression for CLDN-1
(po0.01) and CLDN-5 (po0.01) in patients with chronic
venous insu⁄ciency in comparison with healthy controls on
mRNA as well as protein level (Fig 1 A,B). No statistical di¡er-
ence could be detected for OCLN and CLDN-3 between the
edema group and healthy controls. However, there was a signi¢-
cantly elevated expression (po0.01) on mRNA and protein level
between the leg ulcer group and healthy controls for OCLN and
CLDN-3 (Fig 1A,B). Densitometric evaluation revealed a more
signi¢cantly elevated expression (po0.01) for CLDN-1 and
CLDN-5 on mRNA and protein level after four weeks
of compression therapy in comparison with prior to treatment
for the edema as well as the leg ulcer group (Fig 1A,B). No
statistical di¡erences could be found for OCLN and CLDN-3
solely for the edema group prior to treatment in comparison
with compression therapy treated patients on mRNA- and
protein level. Immunohistochemical staining of skin samples
with antibodies against OCLN, CLDN-1, CLDN-3 and
CLDN-5 indicates that primarily dermal vascular regions are
a¡ected and not of other epidermal or dermal skin cells (data
not shown).
Tight junctions provide a barrier function, inhibiting solute
and water £ow through the paracellular space. There is accumu-
lating evidence that the complexity of the tight junction strand
network and the tightness of TJs are determined by the combina-
tion of the di¡erent tight junction molecules (Tsukita et al, 2000).
For the ¢rst time our results provide evidence that tight junctions
are down-regulated in patients with chronic venous insu⁄ciency
in comparison with healthy controls. Furthermore compression
therapy induces the expression of CLDN-1 and CLDN-5 in pa-
tients with chronic venous insu⁄ciency, which signi¢cantly di¡ers
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from the expression of healthy controls as well as patients prior to
treatment.Whether up-regulation of tight junction molecules can
be directly associated with the mode of treatment requires further
investigations. Compression therapy may tighten the paracellular
barrier via elevated expression of speci¢c tight junctions and may
prevent the progression of chronic venous insu⁄ciency due to in-
hibited permeability of £uid into the perivascular tissue.
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Figure1. Elevated expression for CLDN-1 and CLDN-5 on mRNA- (A) and protein level (B) after compression therapy in patients with chronic
venous insu⁄ciency (A) Densitometric evaluation of generated mRNA-products of OCLN, CLDN-1, CLDN-3 and CLDN-5 in healthy controls (white
bars), edema patients prior to treatment (crossed bar) and after treatment (black bars). (B) Densitometirc evaluation of immunoblots of OCLN, CLDN-1,
CLDN-3 and CLDN-5 in healthy controls (white bars), venous leg ulcer patients prior to treatment (crossed bar) and after treatment (black bars). Data are
means7SEM (n¼ 8 for healthy skin; n¼ 8 for edema group; n¼ 8 for leg ulcer group). The signi¢cance of di¡erence was determined by an unpaired
student’s t test. Di¡erences were considered signi¢cant at po0.01.
Inhibition of Vascular Cell Adhesion Molecule-1 Expression in
Human Dermal Microvascular Endothelial Cells by Iron
Chelators
To the Editor:
Koo et al (2003) recently reported that iron chelators inhibit tumor
necrosis factor-a-mediated vascular cell adhesion molecule-1 expres-
sion in human dermal microvascular endothelial cells, suggesting
that iron plays a critical role in tumor necrosis factor-a-mediated
vascular cell adhesion molecule-1 induction in these cells. As out-
lined by the authors, these ¢ndings may provide new insights into
the role of iron in the pathogenesis of cutaneous in£ammatory dis-
orders, such as psoriasis, contact dermatitis, and ultraviolet-induced
skin changes. They also support previous studies demonstrating that
topically applied iron chelators provide a high level of photoprotec-
tion in both animal and human testing (Bissett et al, 1994).
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